

REPLACED BY  
ART 34 AMDT

## CLAIMS

1. Composition characterized in that it comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein chosen from a CD4 peptide or a derivative of this peptide, or else a monoclonal antibody which binds to the gp120 viral protein and which is capable of activating said gp120 protein in a manner equivalent to the CD4 peptide.
2. Composition according to Claim 1, in which the polyanion is chosen from the group consisting of heparin, heparan sulphate, and a polyanion equivalent to heparin or to heparan sulphate.
3. Composition according to Claim 2, in which the heparin, the heparan sulphate or the polyanion equivalent to heparin or to heparan sulphate has a degree of polymerization dp of 10 to 24.
4. Composition according to Claim 2, in which the heparin, the heparan sulphate or the polyanion equivalent to heparin or to heparan sulphate has a degree of polymerization dp of 12 to 20.
5. Composition according to Claim 2, in which the heparin, the heparan sulphate or the polyanion equivalent to heparin or to heparan sulphate has a degree of polymerization dp of 15 to 17.
6. Composition according to Claim 1, in which the CD4 peptide has the sequence (I) below:  
$$\text{Cys or TPA} - P^1 - \text{Cys} - P^2 - \text{Cys} - P^3 - \text{Cys} - \text{Ala or Gln}$$

- Gly or (D)Asp or Ser - Ser or His or Asn - Xaa<sup>J</sup> - Cys  
- Thr or Ala - Cys - Xaa<sup>k</sup> - NH<sub>2</sub>

in which TPA represents thiopropionic acid, Xaa<sup>J</sup>  
5 represents  $\beta$ -naphthylalanine, phenylalanine or  
biphenylalanine, Xaa<sup>k</sup> represents Gly, Val or Ileu, P<sup>1</sup>  
represents 3 to 6 amino acids, P<sup>2</sup> represents 2 to 4  
amino acids and P<sup>3</sup> represents 6 to 10 amino acids, the  
10 amino acids in P<sup>1</sup>, P<sup>2</sup> and P<sup>3</sup> being natural or unnatural,  
identical or different, and P<sup>1</sup>, P<sup>2</sup> and P<sup>3</sup> possibly  
having a common sequence, said peptide having a  
 $\beta$ -hairpin conformation in which the  $\beta$ -turn is made up  
of the amino acid residues Ala or Gln - Gly or DAsp or  
Ser-Ser or His or Asn- Xaa<sup>J</sup> of its sequence (A).

15

7. Composition according to Claim 1, in which the CD4  
peptide is chosen from the sequences ID No. 1 to ID No.  
18 of the sequence listing attached in the appendix.

20 8. Composition according to any one of Claims 1 to 7,  
in which the polyanion and the molecule capable of  
inducing the exposure of the CD4i epitope of the gp120  
viral protein are mixed in said composition.

25 9. Composition according to Claim 8, in which the  
polyanion and the molecule capable of inducing the  
exposure of the CD4i epitope of the gp120 viral protein  
are mixed in said composition in proportions of 1 to  
10 mol of polyanion per 0.5 to 1.5 mol of molecule  
30 capable of inducing the exposure of the CD4i epitope of  
the gp120 viral protein.

10. Composition according to Claim 7, in which the  
polyanion and the molecule capable of inducing the  
35 exposure of the CD4i epitope of the gp120 viral protein

are mixed in said composition in proportions of 5 mol of polyanion per mole of molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein.

5

11. Composition according to any one of Claims 1 to 7, in which the polyanion and the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein are linked to one another in said  
10 composition.

12. Composition according to Claim 11, in which the polyanion and the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein  
15 are linked to one another at one of the ends of the polyanion.

13. Composition according to Claim 11, in which the polyanion and the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein  
20 are linked to one another by means of a spacer arm of the polyethylene glycol type.

14. Method for producing a composition according to  
25 Claim 8, comprising the following steps:

- preparing the polyanion,
- preparing the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein,
- 30 - mixing the polyanion and the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein prepared so as to obtain said composition.

35 15. Method for producing a composition according to

REPLACED BY  
ART 34 AMDT

Claim 11, comprising the following steps:

- preparing the polyanion,
- preparing the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein,
- linking the polyanion and the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein prepared so as to obtain said composition.

10

16. Method of production according to Claim 14 or 15, in which the polyanion is prepared by partial depolymerization of heparin or of heparan sulphate by means of an enzymatic or chemical method.

15

17. Method of production according to Claim 14 or 15, in which, since the molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein is a peptide, it is prepared by solid-phase chemical synthesis or by genetic recombination.

20

18. Use of a composition according to any one of Claims 1 to 7, for preparing a medicinal product.

25

19. Use of a composition according to any one of Claims 1 to 7, for preparing a medicinal product intended for the treatment of AIDS.